Reduced expression in preterm birth of sFLT-1 and PlGF with a high sFLT-1/PlGF ratio in extracellular vesicles suggests a potential biomarker

Sama Hussein
Weina Ju
Stephanie Pizzella
Michael Flory
Chu Chu

See next page for additional authors
Authors
Sama Hussein, Weina Ju, Stephanie Pizzella, Michael Flory, Chu Chu, Yong Wang, and Nanbert Zhong
Reduced expression in preterm birth of sFLT-1 and PlGF with a high sFLT-1/PlGF ratio in extracellular vesicles suggests a potential biomarker

Sama Hussein1†, Weina Ju1†, Stephanie Pizzella2, Michael Flory1, Chu Chu1, Yong Wang2* and Nanbert Zhong1*

1New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, United States, 2Department of Obstetrics and Gynecology, School of Medicine, Washington University, St. Louis, MO, United States

Preterm birth may have a pathological impact on intrauterine development of the fetal brain, resulting in developmental disabilities. In this study, we examine the expression of soluble Fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PlGF), which is one of the vascular endothelial growth factors (VEGFs), as these play a key role in angiogenesis; in particular, we examine their effect on the sFLT-1/PlGF ratio in cases of preterm birth as compared to typical pregnancies. Enzyme-linked immunosorbent assay was performed on samples of maternal-derived plasma and extracellular vesicles-exosomes (EVs-EXs) isolated at the third trimester, consisting of 17 samples from cases of preterm birth and 38 control cases. Our results showed that both sFLT-1 (P=0.0014) and PlGF (P=0.0032) were significantly downregulated in cases of preterm birth compared to controls, while the sFLT-1/PlGF ratio was significantly (P=0.0008) increased in EVs-EXs, but not in maternal plasma. Our results suggest that this reduced expression of sFLT-1 and PlGF with an elevated sFLT-1/PlGF ratio in EVs-EXs may represent a potential biomarker for prediction of PTB.

KEYWORDS
sFlt-1, placental growth factor, biomarker, preterm (birth), PTB, extracellular vehicles (EVs), exosomes (EX)

Introduction

Preterm birth (PTB) has been defined by the World Health Organization (WHO) as any birth before the completion of 37 weeks of gestation. PTB is classified into two major subtypes: spontaneous preterm birth (sPTB) and indicated preterm birth (iPTB). sPTB is in turn categorized into two distinct clinical scenarios: 1) premature onset of labor (POL),
which is characterized by the occurrence of regular contractions with associated cervical change and intact membranes, and 2) preterm premature rupture of membranes (pPROM) (1). iPTB occurs when labor is induced or cesarean section delivery carried out due to maternal or fetal disease (2). PTB is responsible for 75% of perinatal deaths and more than 50% of long-term newborn morbidities, including neurological impairments, blindness, deafness, and chronic lung illness, as well as learning difficulties and psychological, behavioral, and social issues (3, 4).

The placenta regulates the fetal environment by controlling the passage of nutrients and waste materials between the maternal and fetal circulations. Placental abnormalities are the most typical form of complications arising during human pregnancies (5). Many prenatal disorders that result in premature delivery involve placental disturbances, generally categorized as malperfused placenta or inflamed placenta (6). An under-perfused placenta is linked to fetal growth restriction, preterm birth owing to early labor or premature rupture of membranes, premature placental detachment (abruptio placenta), and an increased risk of preeclampsia (7).

Angiogenesis is the formation of new microvessels from larger blood vessels; it is an important aspect of embryogenesis, as vascularization of the placenta is required for adequate transport of nutrition and oxygen to the fetus (5). Placental growth is fastest in the first half of pregnancy, and development of placental vascular branching continues until term (8). From day 21 until the end of the first trimester, villous vasculature increases in terms of number of vessels rather than vessel type. Villous vascular development shifts from branching to non-branching angiogenesis at the 26th week of pregnancy and continues in that form until birth, when mature intermediate villi specializing in gas exchange are developed. Placentation is influenced by oxygen levels, angiogenic growth factor(s), and their natural receptors and antagonists (5).

Placental growth factor (PIGF) is a member of the vascular endothelial growth factor (VEGF) family and is predominantly expressed in the placenta (9). FLT-1, a tyrosine-protein kinase, functions as a cell-surface receptor for VEGFA, VEGFB, and PIGF, and is crucial for the formation of the embryonic vasculature, the control of angiogenesis, and other processes (10). FLT-1 (sFLT-1) and PIGF are each expressed differently in the human placenta during pregnancy. Soluble FLT-1 (sFLT-1) is a protein that inhibits angiogenesis; it acts by adhering to the receptor-binding domains of PIGF and VEGF and blocking their interaction on the cell surface, leading to endothelial dysfunction (11). Correlations can be observed between the impact of these growth factors, along with their patterns of expression throughout a pregnancy, and the development of the villous angioarchitecture. sFLT-1 is necessary for embryonic vascular architecture but not for endothelial cell differentiation (12). PIGF binding to sFLT-1 is more likely to occur in the final trimester and to result in non-branching angiogenesis (9).

Extracellular vesicles (EVs), which include exosomes (EXs), are membranous nanovesicles of endocytic origin, measuring 30-150 nm in diameter, that are generated by most cell types in various organisms. They encapsulate various proteins and nucleic acids (microRNA, messenger RNA, long non-coding RNA, and DNA) and are released into the extracellular space, where they circulate. Endosome-specific tetraspanins, including CD9, CD63, and CD81, are abundant in EV-EX membranes (13, 14). Plasma concentrations of EVs-EXs have been found to be more than 50 times higher in pregnant women compared to non-pregnant women (15). EVs-EXs derived from the placenta have been shown to enter the maternal blood in both healthy and pathologic pregnancies, and their concentration rises more than twofold as the pregnancy proceeds, reaching a peak at term. The quantification of placental EVs-EXs in maternal plasma represents fetal growth and might be a valuable biomarker of placental function (15–17).

In this study, we examine the expression of soluble Fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PlGF) in EVs-EXs isolated from maternal plasma, in PTB as compared to typical control (Ctrl) pregnancies, as PTB is considered to be a placental disease.

Material and methods

Maternal-derived plasma collection:

Plasma samples were obtained from the Department of Obstetrics and Gynecology, Washington University in St. Louis. In total, samples of maternal-derived plasma were collected at the third trimester in 17 cases of PTB, including 8 cases of spontaneous PTB (sPTB) and 9 cases of indicated PTB (iPTB), and 38 typical full-term pregnancies (control); samples were then stored at -80°C until use (Table 1). This study was reviewed and approved by the Institutional Review Board (IRB approval #201707152) of Washington University in St. Louis.

Isolation of EVs-EXs

The System Biosciences EQUILTRA-20A-1 ExoQuick Ultra EV isolation kit for serum and plasma was used for EV isolation.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Number of Cases</th>
<th>Average Gestational Week</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indicated</td>
<td>9</td>
<td>32 ± 9</td>
</tr>
<tr>
<td>Spontaneous</td>
<td>8</td>
<td>35 ± 8</td>
</tr>
<tr>
<td>Control</td>
<td>37</td>
<td>38 ± 8</td>
</tr>
</tbody>
</table>

TABLE 1 Number of cases and gestational week of preterm births vs. controls.
We collected 300 μl of plasma and centrifuged at 3,000 × g for 15 minutes to remove cellular debris. 67 μl of ExoQuick was added to 250 μl of supernatant in a fresh tube, which was incubated at 4°C on ice for 30 minutes. Throughout the incubation period, the mixture was mixed well by inverting or flicking the tube. Subsequently, the ExoQuick/plasma mixture was centrifuged at 3,000 g for 10 minutes at room temperature. After centrifugation, the EVs-EXs appeared as a beige or white pellet at the bottom of the tube. The supernatant was carefully aspirated off, and any leftover ExoQuick solution was spun down and completely removed by aspiration. The pellet was then resuspended in 200 μl of Buffer B, and 200 μl of Buffer A was added to the EV-EX mixture. The purification column was centrifuged at 1,000 x g for 30 seconds to remove the storage buffer. It was then washed by adding 500 μl of Buffer B on top of the resin, centrifuging at 1,000 x g for 30 seconds, and then discarding the flow. This step in the process was repeated once. The resin was prepared for sample loading by adding 100 μl of Buffer B on top of it. Finally, the EV-EX mixture was added, and the column was mixed at room temperature on a rotating shaker for 5 minutes. Purified EV-EX was obtained after centrifugation at 1,000 x g for 30 seconds.

Quantification and normalization of placental EVs-EXs

CD9, a membrane-specific marker of EVs-EXs, was used to represent the internal level of gene expression in EVs-EXs; this was employed for normalization of the expression of PlGF and sFLT-1 in EVs-EXs.

ELISA

A dilution of the plasma/EVs-EXs (2μl in 4 ml PBS, pH 7.4) was adjusted to the optical density (OD280) indicating 0.04 ng/μl using a nanodrop spectrophotometer. Polystyrene 96-well plates were coated with 50 μl of diluted plasma in PBS and were left at room temperature for one hour on a laboratory rocker; this was followed by incubation overnight at 4°C. Excess plasma was removed from the coated plates; subsequently, 250 μl of blocking buffer (5% milk in PBS) was added and the plates were incubated overnight in a fridge at 4°C. After the incubation period, the blocking buffer was removed and 50 μl per well of primary antisera diluted in PBST (PBS + 0.05% Tween-20) was added in ratios of 1:500, 1:200, and 1:400 for anti-CD9 antibody (Monoclonal Santa Cruz sc-13118), PlGF polyclonal antibody (Invitrogen cat#31460), was used for PlGF and sFLT-1 wells; the plates were covered with aluminum foil and incubated at 37°C for one hour. Next, the plates were washed four times using 300 μl per well of PBST and incubated with 100 μl per well of Thermo Scientific Pierce™ TMB Substrate Kit (Thermo Scientific, cat #PI34021: 1:1 peroxide solution and peroxidase substrate) at RT for 30 min on a laboratory rocker, covered with aluminum foil. The reaction was halted by the addition of 100 μl per well of 20% H2SO4, and the absorbance was measured on a microplate reader SpectraMax M3 at 450 nm. Finally, the sFLT-1/PlGF ratio for each sample was determined.

Statistical analysis

Each sample was measured in duplicate and the average of the two measurements was computed. We computed p-values using the mean of PTB samples against those from typical Ctrl pregnancies. The data collected were tallied, sorted, and statistically evaluated; the normality of the distributions of the optical densities was examined using the Shapiro–Wilk test. All variables were significantly non-normal, with a pronounced rightward skew. Variables were therefore square root transformed, achieving reasonably normal distributions. Differences between groups were analyzed using unpaired two-tailed t-tests, with no adjustments needed for unequal variances. Analyses were performed using version 16.0 of the Stata statistical package (StataCorp, 2019: Stata Statistical Software: Release 16; College Station, TX: StataCorp LLC).

Results

We first tested whether women who gave birth to a preterm fetus had altered levels of sFLT-1 and PlGF, as measured with plasma and EVs-EXs. As shown in Table 2, individual measurement of sFLT-1 and PlGF indicated that there was little difference in the level of either sFLT-1 or PlGF in PTB samples as compared to controls, showing no statistical significance with P > 0.05. There was also no significant difference in terms of the sFLT-1/PlGF ratio in plasma (Figure 1). Our immediate hypothesis was that this non-significance was a result of heterogenous sampling in our study; i.e., among 17 PTB samples, nine were from cases of iPTB and eight were from cases of sPTB, which could interfere with the results. To verify this, we analyzed our data by separating iPTB from sPTB samples and repeating the statistical analysis. Surprisingly, there was no significant
effect for sPTB or iPTB in three comparisons (namely, sPTB vs. Ctrl, iPTB vs. Ctrl, and PTB vs. Ctrl; P > 0.05, data not shown). Because there were no statistical differences in the comparisons of sPTB vs. iPTB vs. PTB, we decided to combine sPTB with iPTB, treating them as a single group for subsequent analyses. Considering the fact that both sFLT-1 and PlGF are involved in placental development, measurement of placental sFLT-1 and PlGF would provide a more accurate reflection of their expression in pregnancy. We therefore reanalyzed sFLT-1 and PlGF levels, and the sFLT-1/PlGF ratio, with EVs-EXs that were isolated from maternal plasma but released from trophoblasts (15, 16). Indeed, the results of this analysis showed that there was a striking difference between the sample groups in sFLT-1, PlGF, and sFLT-1/PlGF ratio within EVs-EXs, when CD9 was used to normalize the assay (Figure 2). The corresponding P values were 0.0014 for sFLT-1/CD9, 0.0032 for PlGF/CD9, and 0.0008 for sFLT-1/PlGF. If CD9 was not used for normalization, PlGF level was still found to be significantly different, with P = 0.0003, although this was not the case for sFLT-1 level, with P > 0.05.

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>Biomarker</th>
<th>Median in Preterm</th>
<th>Median in Control</th>
<th>P-Value</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVs-EXs</td>
<td>PlGF</td>
<td>0.1292</td>
<td>0.3345</td>
<td>0.0003</td>
<td>Significant</td>
</tr>
<tr>
<td>EVs-EXs</td>
<td>PlGF/CD9</td>
<td>1.2857</td>
<td>4.3520</td>
<td>0.0032</td>
<td>Significant</td>
</tr>
<tr>
<td>EVs-EXs</td>
<td>sFLT-1</td>
<td>0.1733</td>
<td>0.2001</td>
<td>0.9997</td>
<td>Non-Significant</td>
</tr>
<tr>
<td>EVs-EXs</td>
<td>sFLT-1/CD9</td>
<td>1.9224</td>
<td>2.6671</td>
<td>0.0014</td>
<td>Significant</td>
</tr>
<tr>
<td>EVs-EXs</td>
<td>sFLT-1/PlGF</td>
<td>0.9578</td>
<td>0.5226</td>
<td>0.0008</td>
<td>Significant</td>
</tr>
<tr>
<td>Maternal plasma</td>
<td>PlGF</td>
<td>0.0688</td>
<td>0.0833</td>
<td>0.8844</td>
<td>Non-Significant</td>
</tr>
<tr>
<td>Maternal plasma</td>
<td>sFLT-1</td>
<td>0.3385</td>
<td>0.3918</td>
<td>0.5207</td>
<td>Non-Significant</td>
</tr>
<tr>
<td>Maternal plasma</td>
<td>sFLT-1/PlGF</td>
<td>4.9779</td>
<td>5.2004</td>
<td>0.6501</td>
<td>Non-Significant</td>
</tr>
</tbody>
</table>

**Discussion**

The primary underlying mechanism in numerous pregnancy complications is now understood to be disorders of placentation (18). Many factors influence the health of the placenta, including ethnicity, history of smoking cigarettes, high blood pressure, multiple gestation pregnancy, maternal blood-clotting disorders, history of uterine surgery (such as a cesarean delivery), history of placental problems, maternal substance abuse (such as cocaine use), abdominal trauma (such as from a fall or blunt trauma), maternal age (as women over the age of 40 years have a higher risk of developing placental problems), and premature rupture of membranes (because the risk of placental problems increases when the amniotic sac ruptures too early). Phenotypically, these factors may result in adverse pregnancy outcomes, such as miscarriage or stillbirth, IUGR, preeclampsia, or spontaneous preterm birth, which are considered to be placental diseases. Pathogenically, these diseases may share abnormal development and differentiation of the placenta at an early stage of placentation, which may impact placental angiogenesis.

![Figure 1](image_url)

*Figure 1*

Boxplots overlaid with scatterplots showing median sFLT-1, PlGF, and sFLT1/PlGF ratio in maternal plasma, comparing preterm birth (PTB) and controls (Ctrl). (A) sFLT-1 in PTB (0.5385) vs. Ctrl (0.3918), (B) PlGF in PTB (0.0688) vs. Ctrl (0.0833), and (C) sFLT-1/PlGF ratio in PTB (4.9779) vs. Ctrl (5.2004) showed that sFLT-1, PlGF and sFLT-1/PlGF were not significant in compared to Ctrl groups.
Molecularly, altered placental angiogenesis, under the influence of the risk factors mentioned above, may result from differential gene expression of angiogenic factors, causing these angiogenic factors to be up- or down-regulated in the placenta, which would also be reflected in maternal circulation. Therefore, alteration of the pro- and anti-angiogenic proteins that have been identified and characterized in relation to each individual disorder could be applied as a biomarker that can be clinically used to predict pregnancy disorder(s), such as preeclampsia or miscarriage.

In preeclampsia (PE) it has been well established that increased levels of sFLT-1 and reduced levels of PlGF may be the underlying pathophysiology (19). The sFLT-1/PlGF ratio has been demonstrated to be elevated in pregnant women 4-5 weeks before the clinical onset of preeclampsia (20). In intrauterine growth retardation (IUGR), few studies have investigated maternal serum levels of sFLT-1 and PlGF. According to one report, the median level of sFLT-1 is significantly greater in women who experience PE and IUGR compared to controls, whereas the median level of PlGF is lower (21). Additionally, a previous study on mice models of fetal growth retardation has shown that elevated sFLT-1 levels disrupt vascularization in the murine placenta, impair placental function, and result in fetuses with fetal growth retardation (22). Finally, in relation to miscarriage, it has been reported that concentrations of sFLT-1 and PlGF are significantly lower in a subgroup of participants with threatened miscarriage who subsequently experience miscarriage, compared to asymptomatic controls (10); the same has been observed in cases of ectopic pregnancy or missed abortion, compared with healthy intrauterine pregnancies (23).

Previously, we have found that cytokine–cytokine receptor interaction is the most common and the most enriched pathway observed in spontaneous preterm birth and spontaneous miscarriage. Ten genes (CCL3, TNF, CCL2, CXCL3, TNFRSF8, CCL4, CXCL10, CXCR4, CCL3L3, and CCL4L1) that are commonly differentially expressed in both sPTB and spontaneous miscarriage (sM) are largely focused on chemokines (including the CC subfamily), TNF, and TNFRSF8, suggesting that sPTB and sM may share a common pathogenic mechanism. Considering that preterm birth is one of the placental diseases that has been determined to share pathogenic alteration in the early stage of placentation with miscarriage and preeclampsia (17, 24), we measured sFLT-1 and PlGF in our preterm birth cohort. Indeed, our results demonstrated that sFLT-1 and PlGF are differentially expressed in PTB.

CD9, CD63, and CD81 are membrane proteins that have become widely accepted as extracellular vesicle markers. CD63 and CD81 have been previously employed as quantifiers of total extracellular vesicle particles, including exosomes, in circulation in maternal blood (25–27). In this study, CD9 was employed as an internal reference for EVs-EXs as a potential biomarker for prediction of sPTB.
with the sFLT-1/PIGF ratio could be more accurate. This combination may also differentiate sPTB from PE and from IUGR. To further confirm the potential value of employing sFLT-1, PIGF, and sFLT-1/PIGF as a set of biomarkers for prediction of sPTB, further studies should be conducted with a cohort offering a larger sample size at early-stage pregnancy. For this purpose, employing EVs-EXs rather than plasma is highly recommended, not only for the prediction of sPTB but also for intrauterine loss of pregnancy, IUGR, or PE.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Yong Wang Department of Obstetrics and Gynecology School of Medicine, Washington University IRB 201707152. The patients/participants provided their written informed consent to participate in this study.

Author contributions

NZ conceived, designed, and supervised the project study. SH designed experiments and performed experiments with WJ and CC. YW and SP provided the samples. SH and MF performed statistical analysis. SH drafted, and NZ finalized, the manuscript. All authors read and approved the final manuscript.

References


